Revolutionizing Gene Therapies through Rapid, Large DNA Synthesis & Designable Delivery Vehicles

On-demand Webinar

Breakthroughs in gene therapy depend on the ability to build and deliver large, complex DNA constructs quickly, reliably, and at scale. Yet constructs over 5 kb, or those containing LTRs and intricate genomic elements, continue to strain traditional synthesis methods. Even once you have the DNA, today’s go-to delivery vehicles (AAVs, LNPs) often can’t handle those oversized cargoes efficiently.

In this joint webinar, EndoFold, Inc. and Ansa Biotechnologies share results from a proof-of-concept collaboration demonstrating a new path forward: ultra-rapid synthesis of full-length therapeutic constructs paired with next-generation, designable delivery vehicles.

Together, they successfully produced—and delivered—a full-length human dystrophin plasmid (~23 kb + UTRs) as an RNA template for EndoFold’s proprietary AI- + physics-designed delivery platform. The outcome: a powerful demonstration of what’s possible when speed, scale, and delivery innovation converge.

What you’ll learn

How on-demand synthesis enables ultra-large constructs, fast
Discover how Ansa delivered a complex, full-length human dystrophin construct in ~20 business days, a timeline other suppliers could not match.

Why retaining full plasmid complexity matters
Learn how preserving the complete dystrophin sequence enables its immediate use as a therapeutic-scale cargo within EndoFold’s next-generation delivery vehicles.

Evidence of robust expression in human cells
See preliminary expression data validating that these large, complex constructs can be delivered and expressed effectively.